Latest Capital Investment News

PWR Holdings Limited has reported a robust half-year performance with revenues climbing 27.8% and net profit rising 38.6%, underpinned by strategic expansion in motorsports and aerospace sectors. The company also announced a higher fully franked interim dividend of 3 cents per share.

Rio Tinto reported solid 2025 results with an 8% increase in copper equivalent production and disciplined cost management, driving a 9% rise in underlying EBITDA to $25.4 billion. The company marked major project completions and maintained a strong dividend payout.

MaxiPARTS Limited reported a modest 1.8% revenue increase to $139.3 million for the half-year ended December 2025, while net profit after tax dipped slightly by 2%. The company raised its interim dividend to 4.15 cents per share, reflecting confidence in its growth initiatives and cash flow outlook.

Transurban Group has reported a robust turnaround in its half-year results to December 2025, with revenue rising 8.1% and profit rebounding from a loss to $343 million. Major infrastructure projects like Melbourne’s West Gate Tunnel and Sydney’s M7-M12 integration are driving growth and operational momentum.

Bega Cheese Limited reported a strong half-year performance with a 5% revenue increase and a 55% jump in net profit, alongside a higher interim dividend and ongoing operational consolidation.

Capstone Copper forecasts steady 2026 copper output with a $495 million capital expenditure plan focused on key growth projects and exploration in Chile.

Select Harvests Limited has reported a strong FY2025 financial performance with a net profit after tax of $31.8 million and a significant reduction in net debt. The company plans to resume dividend payments in 2026 amid favourable almond market conditions.

Acrow Limited reaffirms its first half FY26 revenue guidance with a 22% increase year-on-year, driven by robust demand in key Australian regions and strategic capital investments.

MLG Oz Limited has delivered a robust half-year performance with revenue climbing 6% and EBITDA soaring 24.5%, underpinned by strong gold sector demand and operational efficiencies.

Rhythm Biosciences has inked a non-exclusive distribution agreement with 4Cyte Pathology to integrate its ColoSTAT® colorectal cancer blood test into a vast pathology network across eastern Australia, aiming to boost adoption and accessibility.

Bellevue Gold Limited has approved a $35-40 million paste plant to boost gold recovery by around 7%, while fully pre-delivering its June 2026 gold hedges, strengthening its financial position for growth and exploration.

Sandon Capital Investments reported a robust 17.1% total shareholder return for the half-year ending December 2025, underpinned by rising dividends and a narrowing discount to net tangible assets. The shift to monthly fully franked dividends signals a strategic focus on steady income for investors.